Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia

Abstract

Objective:The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study compared the effects of once-monthly paliperidone palmitate with daily oral antipsychotics on treatment failure in adults with schizophrenia.

Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery

“…In addition, significant reductions in the utilization of public services (i.e., the number of jail days) were observed, resulting in cost savings. Taken together, these findings indicate that paliperidone palmitate LAI may be a cost-effective treatment option for schizophrenia or schizoaffective disorders from a recovery-oriented perspective, where these findings support previous studies on paliperidone LAI and criminal justice involvement 27,28 . Non-adherence to antipsychotic medication is associated with an increased risk of relapse, the persistence of psychotic symptoms, and higher rates of hospitalization or re-hospitalization 29 .…”

Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia

“…Similarly, the discontinuation rate due to intolerance in a recent 1-year observational study on patients treated with PP was 14.7% 23 and in a recent 15-month study on real-world outcomes of PP in patients with schizophrenia, treatment-emergent AEs leading to study drug discontinuation occurred in 11.9% of patients. 24 The primary objective of the present study was to explore putative metabolic alterations with particular regard to MetS components. It is known that metabolic effects are of concern in patients receiving SGAs.…”

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

“…The lower non-drug costs for paliperidone palmitate treated patients offset approximately 25% of the increased drug costs ($2696/$10,759 per patient); however, total costs (with study drug) remained approximately $8063 greater per patient over the 15 month period (i.e., $6450 greater annually) in the paliperidone palmitate group compared with the oral antipsychotic group. The primary trial results of PRIDE found that paliperidone palmitate significantly delayed time to first treatment failure versus oral antipsychotics (median, 416 days versus 226 days; hazard ratio, 1.43 [95% CI, 1.09 to 1.88]; p ¼ 0.011) among patients with schizophrenia and a history of criminal justice system involvement 10 . Those findings provided further support for conducting this cost effectiveness analysis, which was planned before the study began.…”

“…The primary results of PRIDE found that paliperidone palmitate significantly delayed time to first treatment failure (including both healthcare events and criminal justice system events) versus oral antipsychotics 10 . The objective of the present study was to conduct a cost effectiveness analysis of once monthly paliperidone palmitate versus once daily oral antipsychotic therapy using the effectiveness data from PRIDE.…”